What happened
SI-BONE, Inc. (NASDAQ: SIBN) Chief Executive Officer and director Laura Francis sold 75,000 shares on Nov. 4, leaving 304,256 shares in a trust. The sale was made under a Rule 10b5-1 trading plan dated June 13, 2025.
The shares sold in multiple trades at prices from $25.00 to $25.90, a weighted average of $25.30 and about $1.90 million in total. The shares were held by The David Laura Joint Rev Tr. Francis undertook to give the company, any holder or SEC staff the share count at each price on request.
Francis reported as both an officer and a director, and the Form 4 was signed Nov. 6.
Key numbers
| Metric | Latest | Change | Source |
|---|---|---|---|
| Shares sold | 75,000 shares | SEC Form 4 | |
| Weighted average sale price | $25.30 | SEC Form 4 | |
| Total sale value | $1.90 million | SEC Form 4 | |
| Shares held by trust after sale | 304,256 shares | SEC Form 4 | |
| Sale as share of trust holding before trade | 19.8% | Calculated from SEC Form 4 |
Read more: SI-BONE (SIBN) company research
Why it matters
The sale trims the trust's position without ending Francis' stake. By OptimistFi's calculation, the 75,000 shares were 19.8% of the 379,256 shares the trust held before the trade. The Form 4 lists the trust's shares as indirectly owned and the direct holding separately.
Francis also holds 368,129 shares directly. That total includes 355,697 shares issuable on settlement of restricted stock units. Each unit is a contingent right to receive one share of common stock. The sale touched only the trust's shares and left the directly held position unchanged.
The plan was dated more than a year before the trade. That timing means the sale may reflect a pre-set schedule more than a view on SI-BONE's business.
OptimistFi has argued that SI-BONE's value rests on turning its implant platform's clinical evidence into wider physician adoption and reimbursement, which this sale does not test. The sale leaves that view unchanged.
Stock perps: every US stock that trades as a perpetual future, by leverage, live
What's next
The case also needs a direct salesforce to carry the company into adjacent spinal and pelvic markets and toward profitability. SI-BONE's next quarterly report is the next scheduled check on that progress.
Another Form 4 from Francis would show whether sales under the plan continue.
More from OptimistFi
From OptimistFi Perps
- Top perps movers today: stocks, commodities, FX and indices
- Open interest live: crypto and stock perps by exchange
- All perp markets: price, open interest and funding by venue
- Futures calculator: liquidation price, PnL and fees by exchange
- Perp funding rates live: what longs and shorts pay on every venue
- Stock perps vs tokenized stocks: how US shares trade around the clock
Sources
- SEC Form 4, SI-BONE, Inc. (Laura Francis) — Statement of changes in beneficial ownership covering the Nov. 4, 2026 sale, signed Nov. 6, 2026.
Explore OptimistFi research on SI-BONE, Inc.: https://optimistfi.com/stocks/SIBN
Browse SI-BONE, Inc. company coverage and explore the OptimistFi Thesis-Break Engine.
Browse every company OptimistFi covers at optimistfi.com/stocks, or read the latest evidence-first research.
Find available research on the SI-BONE, Inc. company page.
Originally published on OptimistFi, evidence-first equity research. More at optimistfi.com.
